United Therapeutics (NASDAQ:UTHR) Director Sells $1,269,630.00 in Stock

Key Points

• Christopher Causey, Director of United Therapeutics, sold 3,000 shares of stock at an average price of $423.21, totaling approximately $1.27 million, leading to a 38.14% decrease in his ownership.
• The company's quarterly earnings showed an EPS of $6.41, missing estimates by $0.39, with a 40.36% net margin and revenue of $798.60 million.
• Analysts have issued a consensus rating of "Moderate Buy" for United Therapeutics, with target prices ranging from $295.00 to $564.00.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Causey sold 3,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $423.21, for a total value of $1,269,630.00. Following the transaction, the director directly owned 4,865 shares in the company, valued at $2,058,916.65. This trade represents a 38.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Up 5.3%

NASDAQ UTHR traded up $20.05 on Friday, reaching $400.52. The company had a trading volume of 924,693 shares, compared to its average volume of 848,265. The stock's 50 day moving average is $307.69 and its 200-day moving average is $305.80. The stock has a market cap of $18.07 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 6.08 and a beta of 0.62. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.85 EPS. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

Hedge funds have recently made changes to their positions in the business. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $32,000. Finally, Dunhill Financial LLC lifted its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Jefferies Financial Group increased their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday. Oppenheimer upped their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday. Wells Fargo & Company upped their price objective on United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Bank of America upped their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday. Finally, UBS Group upped their price objective on United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a research report on Thursday. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $429.62.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.